-
Something wrong with this record ?
Comparison of Flow and Compression Properties of Four Lactose-Based Co-Processed Excipients: Cellactose® 80, CombiLac®, MicroceLac® 100, and StarLac®
M. Dominik, B. Vraníková, P. Svačinová, J. Elbl, S. Pavloková, BB. Prudilová, Z. Šklubalová, A. Franc
Language English Country Switzerland
Document type Journal Article
Grant support
MUNI/A/1574/2020
Masarykova Univerzita
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2009
Europe PubMed Central
from 2009
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
- Publication type
- Journal Article MeSH
The utilization of co-processed excipients (CPEs) represents a novel approach to the preparation of orally disintegrating tablets by direct compression. Flow, consolidation, and compression properties of four lactose-based CPEs-Cellactose® 80, CombiLac®, MicroceLac® 100, and StarLac®-were investigated using different methods, including granulometry, powder rheometry, and tablet compaction under three pressures. Due to the similar composition and the same preparation technique (spray drying), the properties of CPEs and their compacts were generally comparable. The most pronounced differences were observed in flowability, undissolved fraction after 3 min and 24 h, energy of plastic deformation (E2), ejection force, consolidation behavior, and compact friability. Cellactose® 80 exhibited the most pronounced consolidation behavior, the lowest values of ejection force, and high friability of compacts. CombiLac® showed excellent flow properties but insufficient friability, except for compacts prepared at the highest compression pressure (182 MPa). MicroceLac® 100 displayed the poorest flow properties, lower ejection forces, and the best mechanical resistance of compacts. StarLac® showed excellent flow properties, the lowest amounts of undissolved fraction, the highest ejection force values, and the worst compact mechanical resistance. The obtained results revealed that higher compression pressures need to be used or further excipients have to be added to all tested materials in order to improve the friability and tensile strength of formed tablets, except for MicroceLac® 100.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21023928
- 003
- CZ-PrNML
- 005
- 20211013134113.0
- 007
- ta
- 008
- 211006s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/pharmaceutics13091486 $2 doi
- 035 __
- $a (PubMed)34575562
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Dominik, Martin $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, Palackého tr. 1946/1, 612 42 Brno, Czech Republic
- 245 10
- $a Comparison of Flow and Compression Properties of Four Lactose-Based Co-Processed Excipients: Cellactose® 80, CombiLac®, MicroceLac® 100, and StarLac® / $c M. Dominik, B. Vraníková, P. Svačinová, J. Elbl, S. Pavloková, BB. Prudilová, Z. Šklubalová, A. Franc
- 520 9_
- $a The utilization of co-processed excipients (CPEs) represents a novel approach to the preparation of orally disintegrating tablets by direct compression. Flow, consolidation, and compression properties of four lactose-based CPEs-Cellactose® 80, CombiLac®, MicroceLac® 100, and StarLac®-were investigated using different methods, including granulometry, powder rheometry, and tablet compaction under three pressures. Due to the similar composition and the same preparation technique (spray drying), the properties of CPEs and their compacts were generally comparable. The most pronounced differences were observed in flowability, undissolved fraction after 3 min and 24 h, energy of plastic deformation (E2), ejection force, consolidation behavior, and compact friability. Cellactose® 80 exhibited the most pronounced consolidation behavior, the lowest values of ejection force, and high friability of compacts. CombiLac® showed excellent flow properties but insufficient friability, except for compacts prepared at the highest compression pressure (182 MPa). MicroceLac® 100 displayed the poorest flow properties, lower ejection forces, and the best mechanical resistance of compacts. StarLac® showed excellent flow properties, the lowest amounts of undissolved fraction, the highest ejection force values, and the worst compact mechanical resistance. The obtained results revealed that higher compression pressures need to be used or further excipients have to be added to all tested materials in order to improve the friability and tensile strength of formed tablets, except for MicroceLac® 100.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vraníková, Barbora $u Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Svačinová, Petra $u Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Elbl, Jan $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, Palackého tr. 1946/1, 612 42 Brno, Czech Republic
- 700 1_
- $a Pavloková, Sylvie $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, Palackého tr. 1946/1, 612 42 Brno, Czech Republic
- 700 1_
- $a Prudilová, Barbora Blahová $u Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, Křížkovského 511/8, CZ-771 47 Olomouc, Czech Republic
- 700 1_
- $a Šklubalová, Zdeňka $u Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Franc, Aleš $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, Palackého tr. 1946/1, 612 42 Brno, Czech Republic
- 773 0_
- $w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 13, č. 9 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34575562 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20211006 $b ABA008
- 991 __
- $a 20211013134110 $b ABA008
- 999 __
- $a ind $b bmc $g 1708134 $s 1144422
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 13 $c 9 $e 20210916 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
- GRA __
- $a MUNI/A/1574/2020 $p Masarykova Univerzita
- LZP __
- $a Pubmed-20211006
